Autologous Platelet-Rich Plasma Drops for Evaporative Dry Eye Disease from Meibomian Gland Dysfunction: A Pilot Study.

PURPOSE

To evaluate the effects of autologous platelet-rich plasma (PRP) drops for evaporative dry eye (EDE) disease from meibomian gland dysfunction (MGD).

METHODS

This is a retrospective, consecutive case series of 20 eyes of 10 patients with EDE from MGD treated with PRP drops from November 2020 to November 2021 at a single outpatient clinic in Ontario, Canada. PRP drops were prepared from whole blood using a two-step centrifugation method. Patients were instructed to instill these drops six times daily for 4 weeks. The Canadian Dry Eye Assessment (CDEA) questionnaire score, patient subjective assessment (PSA) score, first and average non-invasive break-up times (f/a NIBUT), tear meniscus height (TMH), bulbar redness (BR), and meibograph grade (MG) were measured before and after the treatment course.

RESULTS

Significant improvements in dry eye symptoms and tear film parameters were observed. Dry eye symptoms significantly improved as per the CDEA (mean difference (MD) = -5.45, 95% confidence interval (CI) = [-7.9, -3.1], <0.001) and PSA (MD = -2.6, 95% CI = [-3.9, -1.2], <0.001). There were significant improvements in tear film parameters including fNIBUT (MD = 3.85s, 95% CI = [1.2, 6.8], =0.006), aNIBUT (MD = -6.81s, 95% CI = [5.7, 11.1], <0.001) and TMH (MD = 0.08, 95% CI = [0.003, 0.2], =0.045). There was an improvement in conjunctival injection as measured by BR (MD = -0.36, 95% CI = [-0.4, -0.15], =0.373). Five eyes experienced a one-grade improvement in MG (=0.453), and none experienced worsening in MG with treatment. No temporary or permanent adverse effects were noted.

CONCLUSION

Four weeks of PRP therapy resulted in significant functional improvements in dry eye symptoms and tear film quality and quantity. Improvements in conjunctival injection and microstructural improvements in meibomian glands were also observed in some eyes. Overall, PRP is a promising treatment option for patients with EDE from MGD refractory to conventional treatments.